Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert ... Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States. Mehr anzeigen
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and...
New Drug Application (NDA) for LNZ100 for treatment of presbyopia accepted for review by the U.S. Food and Drug Administration (FDA); PDUFA target action date of August 8, 2025 CORXEL and LENZ...
SAN DIEGO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and...
Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment，and maintaining their optimal distance visual acuity...
SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial biopharmaceutical company focused on the development and...
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first...
SAN DIEGO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first...
Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for LNZ100 for the treatment of presbyopia Announced positive topline and capstone data from the Phase 3 CLARITY...
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first...
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -2.97 | -11.6607773852 | 25.47 | 25.8212 | 21.34 | 222951 | 22.82555024 | CS |
| 4 | -7.83 | -25.8160237389 | 30.33 | 33.84 | 21.34 | 197500 | 27.89083881 | CS |
| 12 | -2.5 | -10 | 25 | 38.93 | 21.34 | 157048 | 30.84784646 | CS |
| 26 | 0.835 | 3.85414262636 | 21.665 | 38.93 | 19.9001 | 151248 | 26.87826198 | CS |
| 52 | 6.52 | 40.8010012516 | 15.98 | 38.93 | 14.42 | 165123 | 22.86154251 | CS |
| 156 | 6.52 | 40.8010012516 | 15.98 | 38.93 | 14.42 | 165123 | 22.86154251 | CS |
| 260 | 6.52 | 40.8010012516 | 15.98 | 38.93 | 14.42 | 165123 | 22.86154251 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
